Arrowhead Pharmaceuticals
Presença
Arrowhead Pharmaceuticals é uma das ...
Arrowhead Pharmaceuticals é uma empresa listada sob o símbolo ARWR (US).
Executivos
Veja o organograma con seus 29 executivos principais
Biografias mais buscadas da Arrowhead Pharmaceuticals
- Christopher Anzalone, President, Chief Executive Officer, Director
- Douglass Given, Chairman of the Board
- Mauro Ferrari, Director
Recentes movimentos de executivos em Arrowhead Pharmaceuticals
- Javier San Martin, Chief Medical Officer, deixará a Companhia em 1 de fev. de 2024 (Notícia publicada em 23 de janeiro de 2024).
Criar um alerta
para seguir os movimentos de executivos da Arrowhead Pharmaceuticals.
Biotecnologia
Arrowhead Pharmaceuticals possui 2.281 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Endeavor BioMedicines acaba de anunciar uma arrecadação de fundos de 132 milhões de dólares. (publicado em 25 de abril de 2024).
- Metsera acaba de anunciar uma arrecadação de fundos de 290 milhões de dólares. (publicado em 23 de abril de 2024).
- Histogen has filed for bankruptcy protection (publicado em 19 de abril de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Arrowhead Pharmaceuticals
- Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo - Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data - Arrowhead Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy - Arrowhead Pharmaceuticals, Inc.
- GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen | Arrowhead Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results | Arrowhead Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results | Arrowhead Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy | Arrowhead Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1 | Arrowhead Pharmaceuticals Inc.
- Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease | Arrowhead Pharmaceuticals Inc.
- View more press releases Close
Redes sociais sobre Arrowhead Pharmaceuticals
- Arrowhead Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Arrowhead Pharmaceuticals na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Christopher Anzalone 
Ligue para a Arrowhead Pharmaceuticals em +1 626...
